Natco Pharma Receives Demand Notice of ₹4.92 Crore from NPPA
Natco Pharma received a demand notice from NPPA for ₹4.92 crore, including overcharge, penalty, and interest. The notice alleges overcharging for two drugs between April and November 2023. The company stated there is no material financial or operational impact.
Despite the demand notice, the company explicitly stated that there is no material impact on its financial, operational, or other activities.
The company has received a demand notice for a significant sum, which includes penalties and interest, indicating a negative development.
Natco Pharma Limited has received a Demand Notice dated 12th May, 2026, from the National Pharmaceutical Pricing Authority (NPPA), New Delhi. The notice, issued under para 15 of the Drugs Price Control Order, 2013, directs the company to deposit an amount of ₹4,92,25,923. This amount includes overcharge, penalty, and interest.
The alleged violation pertains to overcharging for two drugs during the period between April 2023 and November 2023. The company has stated that there is no material impact on its financial, operational, or other activities due to this notice.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under regulatory impact. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.